

AMENDMENTS TO THE SPECIFICATION

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 8, lines 6-22, with the following:

Furthermore, the method of treating the blood sample with an aqueous medium including the above-mentioned hemolysate is also preferred. ~~Cationic~~ Anionic surfactants such as higher fatty acid salts, alkyl arylsulfonates, alkyl sulfonates and alkyl sulfonic acid esters; ~~anionic~~ cationic surfactants such as alkyl pyridinium salts, alkyl trimethyl ammonium salts, and alkyl polyoxyethylene amines; non-ionic surfactants such as polyoxyethylene alkyl phenylethers, polyoxyethylene alkylethers, and polyoxyethylene sorbitan fatty acid esters; amphoteric surfactants such alkyl betaines; natural surfactants such as saponin, lecithin and cholic acid; and biocomponents such as complements and snake venom, bee toxin and an enzyme such as protease is a non-limiting specific examples of hemolysates. These hemolysates can be used in the form of an aqueous liquid having 0.0001 to 10 weight percent, preferably 0.001 to 5 wt.%, and particularly preferably 0.005 to 1 wt.%. The aqueous liquid medium may, for example, be water or a mixed medium comprising water and a water-soluble organic solvent.

Appl. No. 09/715,172

*Dit
cont*
The amount of the aqueous liquid used is 50 to 100000 times,
preferably 100 to 10000 times, and further preferably 500 to
2000 times that of the blood sample in terms of volume units.
